patients treated with maxacalcitol (PTH >300 pg/ml; mean maximal diameter of parathyroid glands 11.0 ± 0.7 mm before treatment), divided in two groups: group S gland diameter <11.0 mm versus group L with gland diameter >11.0 mm. Parathyroid volume was measured by ultrasonography.
At 4–24 weeks after administration of maxacalcitol, intact PTH concentrations decreased significantly in group S (), versus group L. Serum calcium increased significantly in group L (), versus group S. Glands larger than 11 mm do not adequately respond to treatment.
patients with SHPT and enlarged parathyroid glands were treated by percutaneous maxacalcitol injection therapy (PMIT) under ultrasonographic guidance consecutively 6 times, followed by i.v. maxacalcitol.
PMIT and subsequent i.v. maxacalcitol administration significantly decreased PTH levels and parathyroid gland volume for at least 12 weeks.
A trial on the long-term administration of maxacalcitol (3 times weekly for 26 weeks subsequent to a 26-week pretrial) in 124 dialysis patients with secondary hyperparathyroidism.
PTH levels fell promptly and significantly and were well controlled for one year. Serum calcium levels rose significantly, but within a physiological range. Hypercalcemia (33.1%) was resolved or ameliorated after the withdrawal or dose reduction of maxacalcitol.
An outpatient treatment regimen using percutaneous maxacalcitol injection therapy (PMIT) on a weekly basis for 4–6 weeks following dialysis.
Intact PTH decreased from 797 to 253 pg/mL. Ultrasonographic examination detected a gradual reduction in parathyroid gland volume from 1.27 to 0.24 cm3.